🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fostering Data Sharing

Search Papers Authors Institutions Grants FAIR About

TheSindex

Fostering Data Sharing

Empowering the data sharing that empowers science — an open, citation-grounded index for datasets.

Product

Search
API
Explore
Rankings

Resources

Methodology
Data Sources
Documentation
Press

Organization

About
Team
Wikidata

© 2026 theSindex. All rights reserved.

Home
Authors
Daniel Shu

Daniel Shu

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis”.

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

The Lancet Oncology(2024)10.1016/s1470-2045(24)00457-1

N/A

1.7DataRank · unranked

70 citations

Bernardo Stefanini, Julia Blanter, Benjamin Adegbite, Fionnuala Crowley, Vincent Yip +18 more

Profiling of syngeneic mouse HCC tumor models as a framework to understand anti–PD‐1 sensitive tumor microenvironments

Hepatology(2022)10.1002/hep.32707

N/A

0DataRank · unranked

59 citations

Ludmila Danilova, James M. Leatherman, Tamara Y. Lopez‐Vidal, Jessica I. Sanchez, Soren Charmsaz +15 more

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma

Cancer Research Communications(2023)10.1158/2767-9764.crc-23-0072

N/A

0DataRank · unranked

32 citations

Mir Lim, Chester Kao, Daniel Shu, Amit G. Singal, Anne M. Noonan +7 more

Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.10.16.562104

N/A

0DataRank · unranked

16 citations

Won Jin Ho, Luciane T. Kagohara, Alexander A. Girgis, Sarah M. Shin, Ludmila Danilova +29 more

Data from Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma

(2023)10.1158/2767-9764.c.6719612.v2

N/A

0DataRank · unranked

0 citations

Mir Lim, Chester Kao, Daniel Shu, Amit G. Singal, Anne M. Noonan +7 more

Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma

Nature Immunology(2024)10.1038/s41590-024-01992-w

N/A

0DataRank · unranked

99 citations

Won Jin Ho, Luciane T. Kagohara, Alexander A. Girgis, Sarah M. Shin, Ludmila Danilova +34 more

Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors

Nature Communications(2025)10.1038/s41467-025-58512-z

N/A

0DataRank · unranked

27 citations

Soren Charmsaz, Hua‐Ling Tsai, Khaled Aziz, Daniel Shu, Kabeer Munjal +25 more

Prion-like Aggregation of Mitochondrial Antiviral Signaling Protein in Lupus Patients Is Associated With Increased Levels of Type I Interferon: MAVS AGGREGATION AND TYPE I IFN IN LUPUS

UNC Libraries(2020)10.17615/612k-f556

N/A

0DataRank · unranked

0 citations

Wen-Hai Shao, Stephen O. Priest, Brendan Hilliard, Matteo Cesaroni, Jenny P.‐Y. Ting +3 more

Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0002

N/A

0DataRank · unranked

11 citations

Won Jin Ho, Daniel Shu, Jennifer N. Durham, Madelena Brancati, Heather Davis Bruning +23 more